Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
117,483,515
-
Shares change
-
-664,011
-
Total reported value, excl. options
-
$623,821,340
-
Value change
-
-$3,868,785
-
Put/Call ratio
-
106%
-
Number of buys
-
42
-
Number of sells
-
38
-
Price
-
$5.31
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q1 2021
As of 31 Mar 2021 Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) had 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 117,483,515 shares of stock of the company.
Largest 10 holders included Matrix Capital Management Company, LP, NEA Management Company, LLC, BAILLIE GIFFORD & CO, BAKER BROS. ADVISORS LP, Capital World Investors, MORGAN STANLEY, Avoro Capital Advisors LLC, PFM Health Sciences, LP, CITADEL ADVISORS LLC, and Point72 Asset Management, L.P..
This table shows 80 institutional shareholders of the security as of 31 Mar 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.